SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 96 filers reported holding SPERO THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $1,000 | -95.5% | 1,934 | -25.1% | 0.00% | – |
Q1 2022 | $22,000 | -45.0% | 2,581 | +4.6% | 0.00% | – |
Q4 2021 | $40,000 | -11.1% | 2,467 | 0.0% | 0.00% | – |
Q3 2021 | $45,000 | +25.0% | 2,467 | -3.6% | 0.00% | – |
Q2 2021 | $36,000 | +12.5% | 2,559 | +18.0% | 0.00% | – |
Q1 2021 | $32,000 | -84.2% | 2,169 | -79.1% | 0.00% | – |
Q4 2020 | $202,000 | +83.6% | 10,400 | +5.9% | 0.00% | – |
Q3 2020 | $110,000 | -22.5% | 9,825 | -6.7% | 0.00% | – |
Q2 2020 | $142,000 | +992.3% | 10,525 | +530.6% | 0.00% | – |
Q1 2020 | $13,000 | -35.0% | 1,669 | -21.4% | 0.00% | – |
Q4 2019 | $20,000 | -13.0% | 2,124 | 0.0% | 0.00% | – |
Q3 2019 | $23,000 | +35.3% | 2,124 | +44.1% | 0.00% | – |
Q2 2019 | $17,000 | -10.5% | 1,474 | 0.0% | 0.00% | – |
Q1 2019 | $19,000 | +216.7% | 1,474 | +44.7% | 0.00% | – |
Q4 2018 | $6,000 | -45.5% | 1,019 | 0.0% | 0.00% | – |
Q3 2018 | $11,000 | -26.7% | 1,019 | 0.0% | 0.00% | – |
Q2 2018 | $15,000 | +7.1% | 1,019 | 0.0% | 0.00% | – |
Q1 2018 | $14,000 | +16.7% | 1,019 | 0.0% | 0.00% | – |
Q4 2017 | $12,000 | – | 1,019 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Atlas Venture Associates IX, LLC | 1,353,303 | $1,962,289 | 10.74% |
Anson Funds Management LP | 3,444,862 | $4,995,050 | 0.83% |
OUP Management Co., LLC | 249,070 | $361,152 | 0.62% |
Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,469,485 | 0.18% |
Murchinson Ltd. | 762,700 | $1,105,915 | 0.14% |
AWM Investment Company, Inc. | 383,400 | $555,930 | 0.08% |
Alphabet Inc. | 889,979 | $1,290,469 | 0.07% |
Novo Holdings A/S | 468,902 | $679,908 | 0.05% |
DAFNA Capital Management LLC | 125,000 | $181,250 | 0.05% |
XTX Topco Ltd | 106,384 | $154,257 | 0.03% |